CBPL.BO · BSE
Chandra Bhagat Pharma Limited
₹49.45
-5.00% (-₹2.6)
Prev. close
₹52.05
Volume
6,000
As of
22 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma Limited, a pharmaceutical company, markets pharmaceutical critical care and health care products in India and internationally. The company offers pharmaceutical formulations, including intravenous and intramuscular injections, oral solids, tablets, capsules, liquid orals, syrup suspensions, injectable liquids, powders, lyophilized ampoules, vials, prefilled syringes, and small and large volume parenteral for various therapeutic categories, such as anti-cancer, anti-infective, antibiotics, anesthesia, hormones, orthopedic, cardiac, cardiovascular, anti-fungal, antiviral, pediatrics, cardiology, nephrology, and neurology to hospitals and health care centers through its own distribution networks and sales force under its own brand. It also promotes and markets specialty chemicals, intermediates, and active pharmaceuticals ingredients. In addition, the company manufactures pharmaceuticals. It exports its products. Chandra Bhagat Pharma Limited was founded in 1944 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Medical Distribution
CEO
Mr. Hemant Chandravadan Bhagat
Headquarters
Mumbai
Employees
45
Website
cbcpharma.comExchange
View on BSE ↗Key stats
Market cap
₹37.31 Cr
P/E ratio (TTM)
12.2
EPS (TTM)
₹4.04
Beta (1Y · daily vs NIFTY 50)
0.34
Beta (5Y · monthly vs NIFTY 50)
0.45
Shares float
12.95 L
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹70.70 Cr | ₹94.08 Cr | ₹119.67 Cr | ₹221.37 Cr | ₹86.72 Cr | ₹112.13 Cr | |
| EBITDA | ₹3.80 Cr | ₹4.30 Cr | ₹3.45 Cr | ₹4.04 Cr | ₹3.84 Cr | ₹7.01 Cr |
| ₹19.00 L | ₹79.70 L | ₹90.54 L | ₹1.53 Cr | ₹85.78 L | ₹3.05 Cr | |
| Diluted EPS | — | ₹1.06 | ₹1.2 | ₹2.03 | ₹1.14 | — |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹60.58 Cr | ₹101.80 Cr | ₹101.53 Cr | ₹94.21 Cr | |
| — | — | ₹18.94 Cr | ₹16.43 Cr | ₹20.86 Cr | ₹16.51 Cr | |
| Stockholders' equity | — | — | ₹27.48 Cr | ₹29.01 Cr | ₹29.97 Cr | ₹33.13 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹5.26 Cr | ₹6.18 Cr | ₹-5.71 Cr | ₹9.24 Cr | |
| Investing cash flow | — | — | ₹-5.90 L | ₹-1.85 Cr | ₹-78.21 L | ₹-43.46 L |
| Financing cash flow | — | — | ₹-4.45 Cr | ₹-5.80 Cr | ₹2.19 Cr | ₹-6.36 Cr |
| Capital expenditure | — | — | ₹-36.85 L | ₹-2.28 Cr | ₹-1.20 Cr | ₹-92.06 L |
| End cash position | — | — | ₹6.44 Cr | ₹4.96 Cr | ₹66.51 L | ₹3.11 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| Chandra Bhagat Pharma Limited | ₹37.31 Cr | ₹49.45 | 12.2 | 1.13 | 9.2% | 0.50 | +29.3% | +15.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.